Stocks · Healthcare · Biotechnology
Structure Therapeutics Inc. GPCR
$27.59 -0.29% Close, Oct 5, 2026 · NASDAQ · Market cap $1.59B
Next earnings report: Nov 5, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- The diluted share count rose 25.4% in a year.
- The stock is 71% below its highest close of the past year.
- The stock is in a downtrend: below its 200-day average, with the 50-day average below the 200-day.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 6, 2026.
How fast revenue, earnings and cash flow are growing.
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 49%
- Accruals (lower is better)Bottom 17%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 43%
- Free-cash-flow yieldBottom 31%
- EBITDA / enterprise valueBottom 31%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 22%
- 6-month returnBottom 6%
- 1-year return vs S&P 500Bottom 46%
- Distance from 52-week highBottom 8%
- Trend checklist (0–4)Bottom 13%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 24%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyTop 10%
- Upside to consensus price targetTop 17%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 44%
- Maximum drawdown, 3 yearsBottom 31%
- Beta vs S&P 500 (lower is better)Top 40%
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Return on invested capital | -18.9% | — | Top 49% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- 0.4%
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -48.27%
- Shareholder yield
- -48.27%
- Share count change, 1 year
- +25.4%
- Share count change, 3-year CAGR
- +23.8%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 6, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 2 of 8
- Average EPS surprise, last 4
- -14.5%
- Average 2-day reaction, last 8
- +1.6%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $90.50
- Target vs current price
- +228.0%
- Analysts with a rating
- 14
- Share rating Buy or Strong Buy
- 100%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 6, 2026 | -25.6% | +4.1% | +6.7% | -5.4% | — |
| May 7, 2026 | +10.3% | -4.1% | -6.8% | -4.4% | +18.4% |
| Feb 26, 2026 | -40.0% | -2.7% | -5.1% | -27.7% | -41.7% |
| Nov 6, 2025 | -2.8% | +3.9% | +11.5% | +2.0% | +160.1% |
| Aug 6, 2025 | -28.6% | -2.2% | +12.4% | +18.2% | +77.3% |
| May 8, 2025 | -12.5% | +0.8% | -10.5% | -19.3% | -36.9% |
| Feb 27, 2025 | +4.3% | +14.8% | +13.5% | +0.6% | +24.0% |
| Nov 13, 2024 | -5.3% | -1.6% | -11.3% | -7.4% | -32.9% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.49 | -$0.39 | -25.6% | — |
| May 7, 2026 | -$0.35 | -$0.39 | +10.3% | — |
| Feb 26, 2026 | -$0.49 | -$0.35 | -40.0% | — |
| Nov 6, 2025 | -$0.37 | -$0.36 | -2.8% | — |
| Aug 6, 2025 | -$0.36 | -$0.28 | -28.6% | — |
| May 8, 2025 | -$0.27 | -$0.24 | -12.5% | — |
| Feb 27, 2025 | -$0.22 | -$0.23 | +4.3% | $1.8M |
| Nov 13, 2024 | -$0.20 | -$0.19 | -5.3% | — |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| Free-cash-flow yield | -14.09% | — | — | Bottom 31% |
| Earnings yield | -10.98% | — | — | Bottom 43% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -12.7%
- 200-day average slope (20 days)
- -1.9%
- Distance from 50-day average
- -37.7%
- Distance from 200-day average
- -48.3%
- RSI (14)
- 16.7
- Relative volume
- 1.00×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 59.2%
- Volatility vs own 5-year history
- 22th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.96
- Correlation with S&P 500
- 0.15
- Current drawdown from 1-year high
- -70.6%
- Maximum drawdown, 3 years
- -81.0%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Oct 31, 2023 | Apr 8, 2025 | -81.0% | 359 days | 192 days (Jan 13, 2026) |
| Jan 21, 2026 | Oct 5, 2026 | -70.6% | 177 days | Not yet recovered |
| Jul 3, 2023 | Aug 7, 2023 | -36.3% | 24 days | 38 days (Sep 29, 2023) |
| Mar 3, 2023 | Mar 28, 2023 | -20.1% | 17 days | 39 days (May 23, 2023) |
| Feb 3, 2023 | Feb 21, 2023 | -17.3% | 11 days | 8 days (Mar 3, 2023) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $1.59B
- EPS, diluted (TTM)
- -$3.03
- Revenue (TTM)
- $0
- 52-week range
- $25.59 – $94.90
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | -$3.9M |
| Operating income | -$37.7M | -$52.6M | -$102.8M | -$158.2M | -$287.6M |
| Net income | -$40.0M | -$51.3M | -$89.6M | -$122.5M | -$141.2M |
| EPS (diluted) | -$1.20 | -$1.44 | -$2.43 | -$2.34 | -$2.40 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$34.0M | -$36.5M | -$46.8M | -$61.7M | -$65.7M | $33.0M | -$76.2M | -$106.2M |
| EPS (diluted) | -$0.60 | -$0.63 | -$0.81 | -$1.08 | -$1.11 | $0.60 | -$1.05 | -$1.47 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$32.2M | -$46.1M | -$79.5M | -$116.6M | -$222.2M |
| Capital expenditure | -$1.2M | -$155,000 | -$2.2M | -$1.3M | -$3.6M |
| Free cash flow | -$33.4M | -$46.3M | -$81.7M | -$117.9M | -$225.8M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $0 | $0 | $472.3M | $514.6M | $767.2M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $1.34B
- Total assets
- $1.43B
- Total liabilities
- $71.0M
- Total debt
- $6.2M
- Net debt
- -$266.4M
- Shareholders’ equity
- $1.35B
As of Jun 30, 2026 (filed Aug 6, 2026).
Short interest
- Shares sold short
- 6,605,011
- Days to cover
- 5.23
- Change vs previous report
- +12.8%
FINRA short interest, settlement date Sep 15, 2026.